[
  {
    "indication": "the u",
    "approval_date": "2025-06-20",
    "year": 2025,
    "confidence": "high",
    "source_text": "Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullo"
  },
  {
    "indication": "the u",
    "approval_date": "2025-04-18",
    "year": 2025,
    "confidence": "high",
    "source_text": "Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chr"
  },
  {
    "indication": "the us as the first-ever biologic medicine for patients with copd",
    "approval_date": "2024-09-27",
    "year": 2024,
    "confidence": "high",
    "source_text": "Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD"
  },
  {
    "indication": "the us as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps",
    "approval_date": "2024-09-13",
    "year": 2024,
    "confidence": "high",
    "source_text": "Dupixent Approved in the US as First and Only Treatment for Adolescents with Chronic Rhinosinusitis "
  },
  {
    "indication": "children aged 1 year and older with eosinophilic esophagitis (eoe)",
    "approval_date": "2024-01-25",
    "year": 2024,
    "confidence": "high",
    "source_text": "Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and"
  },
  {
    "indication": "atopic dermatitis with moderate-to-severe hand and foot involvement",
    "approval_date": "2024-01-16",
    "year": 2024,
    "confidence": "high",
    "source_text": "Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with M"
  },
  {
    "indication": "prurigo nodularis",
    "approval_date": "2022-09-29",
    "year": 2022,
    "confidence": "high",
    "source_text": "Dupixent (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis"
  },
  {
    "indication": "children aged 6 months to 5 years with moderate-to-severe atopic dermatitis",
    "approval_date": "2022-06-07",
    "year": 2022,
    "confidence": "high",
    "source_text": "FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years w"
  },
  {
    "indication": "adults and children aged 12 and older with eosinophilic esophagitis",
    "approval_date": "2022-05-20",
    "year": 2022,
    "confidence": "high",
    "source_text": "FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with "
  },
  {
    "indication": "expands approval",
    "approval_date": "2021-10-20",
    "year": 2021,
    "confidence": "high",
    "source_text": "FDA Expands Approval of Dupixent (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to"
  },
  {
    "indication": "approves new dupixent",
    "approval_date": "2020-06-19",
    "year": 2020,
    "confidence": "high",
    "source_text": "FDA Approves New Dupixent (dupilumab) Pre-Filled Pen Designed to Support More Convenient Self-Admini"
  },
  {
    "indication": "children aged 6 to 11 years with moderate-to-severe atopic dermatitis",
    "approval_date": "2020-05-26",
    "year": 2020,
    "confidence": "high",
    "source_text": "FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Mo"
  },
  {
    "indication": "chronic rhinosinusitis with nasal polyposis",
    "approval_date": "2019-06-26",
    "year": 2019,
    "confidence": "high",
    "source_text": "FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis"
  },
  {
    "indication": "moderate-to-severe atopic dermatitis in adolescents",
    "approval_date": "2019-03-11",
    "year": 2019,
    "confidence": "high",
    "source_text": "FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents"
  },
  {
    "indication": "moderate-to-severe asthma",
    "approval_date": "2018-10-19",
    "year": 2018,
    "confidence": "high",
    "source_text": "FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma"
  },
  {
    "indication": "eczema",
    "approval_date": "2017-03-28",
    "year": 2017,
    "confidence": "high",
    "source_text": "FDA Approves Dupixent (dupilumab) for Eczema"
  }
]